Ruhr University Bochum press release
A drug that is already in clinical trials against hepatitis C virus can also prevent hepatitis E virus from replicating.
Around 70,000 people die each year from infections with hepatitis E virus. There is currently neither a vaccine nor a specific drug against this virus. This could change with the identification of bemnifosbuvir as a compound effective against hepatitis E virus. An international research team from Bochum, Germany, Heidelberg, Germany, and Beijing, China, has filtered this so called nucleotide/nucleoside analogue out of a library of such active substances. Since the drug is also effective against the hepatitis C virus and is already in clinical trials for this indication, the researchers hope that it could also become available as a treatment option against the hepatitis E virus in the foreseeable future. They report their findings in the journal Gut.
Read the full press release here.
Source : Ruhr University Bochum
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.